Correlated diffusion imaging

BackgroundProstate cancer is one of the leading causes of cancer death in the male population. Fortunately, the prognosis is excellent if detected at an early stage. Hence, the detection and localization of prostate cancer is crucial for diagnosis, as well as treatment via targeted focal therapy. New imaging techniques can potentially be invaluable tools for improving prostate cancer detection and localization.MethodsIn this study, we introduce a new form of diffusion magnetic resonance imaging called correlated diffusion imaging, where the tissue being imaged is characterized by the joint correlation of diffusion signal attenuation across multiple gradient pulse strengths and timings. By taking into account signal attenuation at different water diffusion motion sensitivities, correlated diffusion imaging can provide improved delineation between cancerous tissue and healthy tissue when compared to existing diffusion imaging modalities.ResultsQuantitative evaluation using receiver operating characteristic (ROC) curve analysis, tissue class separability analysis, and visual assessment by an expert radiologist were performed to study correlated diffusion imaging for the task of prostate cancer diagnosis. These results are compared with that obtained using T2-weighted imaging and standard diffusion imaging (via the apparent diffusion coefficient (ADC)). Experimental results suggest that correlated diffusion imaging provide improved delineation between healthy and cancerous tissue and may have potential as a diagnostic tool for cancer detection and localization in the prostate gland.ConclusionsA new form of diffusion magnetic resonance imaging called correlated diffusion imaging (CDI) was developed for the purpose of aiding radiologists in cancer detection and localization in the prostate gland. Preliminary results show CDI shows considerable promise as a diagnostic aid for radiologists in the detection and localization of prostate cancer.

[1]  K. Hosseinzadeh,et al.  Endorectal diffusion‐weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue , 2004, Journal of magnetic resonance imaging : JMRI.

[2]  D P Dearnaley,et al.  Distortion-corrected T2 weighted MRI: a novel approach to prostate radiotherapy planning. , 2007, The British journal of radiology.

[3]  Ian M Thompson,et al.  Prostate‐specific antigen: A review of the validation of the most commonly used cancer biomarker , 2004, Cancer.

[4]  R. Gittes,et al.  Prostate-specific antigen. , 1987, The New England journal of medicine.

[5]  Baris Turkbey,et al.  Imaging techniques for prostate cancer: implications for focal therapy , 2009, Nature Reviews Urology.

[6]  J. Machan,et al.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. , 2010, AJR. American journal of roentgenology.

[7]  D P Dearnaley,et al.  Comparison of MRI with CT for the radiotherapy planning of prostate cancer: a feasibility study. , 1999, The British journal of radiology.

[8]  L. Holmberg,et al.  The sextant protocol for ultrasound-guided core biopsies of the prostate underestimates the presence of cancer. , 1997, Urology.

[9]  Masoom A Haider,et al.  Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. , 2007, AJR. American journal of roentgenology.

[10]  Denis Le Bihan,et al.  Imagerie de diffusion in-vivo par résonance magnétique nucléaire , 1985 .

[11]  F. Montorsi,et al.  PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  P. P. Iu,et al.  ESUR prostate MR guidelines. , 2013, European radiology.

[13]  S. Morrison,et al.  Targeting, Imaging, and Therapy Using a Humanized Antiprostate Stem Cell Antigen (PSCA) Antibody , 2007, Journal of immunotherapy.

[14]  A. Chokkalingam,et al.  Prostate cancer epidemiology. , 2006, Frontiers in bioscience : a journal and virtual library.

[15]  Yael Paran,et al.  Water diffusion in the different microenvironments of breast cancer , 2004, NMR in biomedicine.

[16]  Baris Turkbey,et al.  Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images? , 2011, Radiology.

[17]  J. E. Tanner,et al.  Spin diffusion measurements : spin echoes in the presence of a time-dependent field gradient , 1965 .

[18]  H. Wijkstra,et al.  Correlation of transrectal ultrasound, computer analysis of transrectal ultrasound and histopathology of radical prostatectomy specimen , 2001, Prostate Cancer and Prostatic Diseases.

[19]  E Bellon,et al.  The contribution of magnetic resonance imaging to the three-dimensional treatment planning of localized prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[20]  F. Algaba,et al.  Impact of prostate cancer multifocality on its biology and treatment. , 2010, Journal of endourology.

[21]  J. Fütterer,et al.  ESUR prostate MR guidelines 2012 , 2012, European Radiology.

[22]  Ashesh B Jani,et al.  Early prostate cancer: clinical decision-making , 2003, The Lancet.

[23]  A R Padhani,et al.  Diffusion-weighted MRI: a new functional clinical technique for tumour imaging. , 2006, The British journal of radiology.

[24]  H. VanBrocklin,et al.  Assessment of an 18F-Labeled Phosphoramidate Peptidomimetic as a New Prostate-Specific Membrane Antigen–Targeted Imaging Agent for Prostate Cancer , 2009, Journal of Nuclear Medicine.

[25]  Ying Liu,et al.  MRl of Prostate Cancer Antigen Expression for Diagnosis and lmmunotherapy , 2012, PloS one.

[26]  F. Salazar,et al.  An affinity matured minibody for PET imaging of prostate stem cell antigen (PSCA)-expressing tumors , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  D. Collins,et al.  Diffusion-weighted MRI in the body: applications and challenges in oncology. , 2007, AJR. American journal of roentgenology.

[28]  Namkug Kim,et al.  Functional MR imaging of prostate cancer. , 2007, Radiographics : a review publication of the Radiological Society of North America, Inc.

[29]  V. Simplaceanu,et al.  Tissue water content and nuclear magnetic resonance in normal and tumor tissues. , 1975, Cancer research.

[30]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[31]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[32]  Christina Bougatsos,et al.  Screening for Prostate Cancer: A Review of the Evidence for the U.S. Preventive Services Task Force , 2011, Annals of Internal Medicine.